Home Cart Sign in  
Chemical Structure| 1202402-40-1 Chemical Structure| 1202402-40-1

Structure of Ciforadenant
CAS No.: 1202402-40-1

Chemical Structure| 1202402-40-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

CPI-444 is an orally administered antagonist of the adenosine A2A receptor. Upon oral administration, CPI-444 binds to adenosine A2A receptors expressed on the surface of immune cells, including T-lymphocytes, natural killer (NK) cells, macrophages and dendritic cells (DCs).

Synonyms: CPI-444; V81444

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Ciforadenant

CAS No. :1202402-40-1
Formula : C20H21N7O3
M.W : 407.43
SMILES Code : NC1=NC(C2=CC=C(C)O2)=C(N=NN3CC4=NC(CO[C@@H]5COCC5)=CC=C4)C3=N1
Synonyms :
CPI-444; V81444
MDL No. :MFCD31540410
InChI Key :KURQKNMKCGYWRJ-HNNXBMFYSA-N
Pubchem ID :44537963

Safety of Ciforadenant

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Related Pathways of Ciforadenant

GPCR

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
CD8+ T cells 10 μM 3 days To evaluate the effect of Ciforadenant on reversing Spp1hi-TAM-mediated suppression of CD8+ T cell proliferation. Results showed that Ciforadenant significantly reduced the suppression of T cell proliferation by Spp1hi-TAMs. PMC11779626

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice CRPC model Oral gavage 10 mg/kg Once daily for 10 consecutive days To evaluate the inhibitory effect of Ciforadenant on CRPC growth. Results showed that Ciforadenant significantly reduced CRPC growth and decreased the frequency and number of exhausted CD8+ T cells. PMC11779626

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT03708224 Cancer Carcin... More >>oma Squamous Cell Carcinoma Head and Neck Cancer Less << Phase 2 Not yet recruiting November 30, 2025 United States, California ... More >> University of San Francisco, California San Francisco, California, United States, 94115 Less <<
NCT03337698 Carcinoma, Non-Small-Cell Lung Phase 1 Phase 2 Recruiting April 20, 2022 United States, Connecticut ... More >> Smilow Cancer Hospital at Yale New Haven Recruiting New Haven, Connecticut, United States, 06510 United States, Massachusetts Massachusetts General Hospital Not yet recruiting Boston, Massachusetts, United States, 02114 Dana-Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02215 United States, New York Columbia University Medical Center; Research Pharmacy, Irving Pavillion, Ip 7-749 Recruiting New York, New York, United States, 10032 United States, Tennessee Sarah Cannon Research Institute Recruiting Nashville, Tennessee, United States, 37203 Australia, Victoria Peter Mac Callum Cancer Center Recruiting East Melbourne, Victoria, Australia, 3002 France Centre Léon Bérard Recruiting Lyon, France, 69008 Hôpital Nord Not yet recruiting Marseille, France, 13915 Institut Universitaire du Cancer de Toulouse-Oncopole; PHARMACIE Recruiting Toulouse, France, 31100 Korea, Republic of Seoul National University Hospital Recruiting Seoul, Korea, Republic of, 03080 Severance Hospital, Yonsei University Health System; Pharmacy Recruiting Seoul, Korea, Republic of, 03722 University of Ulsan College of Medicine - Asan Medical Center (AMC) - Asan Cancer Center (ACC) Recruiting Songpa-gu, Korea, Republic of, 05505 Spain Clínica Universidad de Navarra Recruiting Pamplona, Navarra, Spain, 31620 Hospital Universitari Vall d'Hebron Recruiting Barcelona, Spain, 08035 Fundación Jimenez Díaz Recruiting Madrid, Spain, 28040 South Texas Accelerated Research Therapeutics Madrid - CIOCC - Universitario Sanchinarro Recruiting Madrid, Spain, 28050 United Kingdom Barts Cancer Institute Recruiting London, United Kingdom, E1 2AT Royal Marsden Hospital; Institute of Cancer Research Recruiting Sutton, United Kingdom, SM2 5PT Less <<
NCT03454451 Non-Small Cell Lung Cancer ... More >> Renal Cell Cancer Colorectal Cancer Triple Negative Breast Cancer Cervical Cancer Ovarian Cancer Pancreatic Cancer Endometrial Cancer Sarcoma Squamous Cell Carcinoma of the Head and Neck Bladder Cancer Metastatic Castration Resistant Prostate Cancer Less << Phase 1 Recruiting December 2023 United States, Connecticut ... More >> Yale School of Medicine Recruiting New Haven, Connecticut, United States, 06519 Contact: Site Coordinator    203-785-3482    ycci@yale.edu    Principal Investigator: Patricia LoRusso, MD          United States, Florida University of Miami Recruiting Miami, Florida, United States, 33136 Contact: Study Coordinator    305-243-0865    txl351@med.miami.edu    Principal Investigator: Jaime Merchan, MD          United States, Illinois The University of Chicago Recruiting Chicago, Illinois, United States, 60637 Contact: Site Coordinator    773-702-1835    mweist@medicine.bsd.uchicago.edu    Principal Investigator: Jason Luke, MD          United States, New York Icahn School of Medicine at Mount Sinai Recruiting New York, New York, United States, 10029 Contact: Site Coordinator    212-824-7309    ccto@mssm.edu    Principal Investigator: Thomas Marron, MD          United States, North Carolina Carolina BioOncology Institute Recruiting Huntsville, North Carolina, United States, 28078 Contact: Study Coordinator    704-947-6599    info@carolinabiooncology.org    Principal Investigator: John Powderly          United States, Oklahoma University of Oklahoma - Stephenson Cancer Center Recruiting Oklahoma City, Oklahoma, United States, 73104 Contact: Site Coordinator    405-271-1112    SCC-Clinical-Trials-Office@ouhsc.edu    Principal Investigator: Abhishek Tripathi, MD          United States, Tennessee Sarah Cannon Research Institute Recruiting Nashville, Tennessee, United States, 37203 Contact: Site Coordinator    615-329-7274    asksarah@sarahcannon.com    Principal Investigator: Melissa Johnson, MD          United States, Texas Mary Crowley Cancer Research Recruiting Dallas, Texas, United States, 75230 Contact: Study Coordinator    972-566-3000    information@marycrowley.org    Principal Investigator: Minal Barve, MD          United States, Wisconsin Froedtert Hospital & Medical College of Wisconsin Recruiting Milwaukee, Wisconsin, United States, 53226 Contact: Site Coordinator    414-805-8900    CCCTO@mcw.edu    Principal Investigator: Matthew Riese, MD Less <<
NCT03237988 Healthy Subjects Phase 1 Completed - United States, Texas ... More >> Covance Clinical Research Unit Dallas, Texas, United States, 75247 Less <<
NCT02655822 Non-Small Cell Lung Cancer ... More >> Malignant Melanoma Renal Cell Cancer Triple Negative Breast Cancer Colorectal Cancer Bladder Cancer Metastatic Castration Resistant Prostate Cancer Less << Phase 1 Recruiting October 2021 -
NCT02764892 Parkinson's Disease PHASE1 COMPLETED 2025-03-13 -
NCT01634568 Parkinson's Disease PHASE1 COMPLETED 2025-02-12 Hammersmith Medicines Research... More >>, London, NW10 7EW, United Kingdom Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.45mL

0.49mL

0.25mL

12.27mL

2.45mL

1.23mL

24.54mL

4.91mL

2.45mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories